The company’s shares closed last Wednesday at $3.95. The stock has a consensus analyst rating of "Buy." See what the analysts say. Buy or Sell this stock? View the latest ratings for BCRX. Biocryst Pharmaceuticals Inc's average analyst price target is higher than 16.43% of stocks in the mid … See BIOCRYST PHARMACEUTICALS INC (BCRX.MX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Get the latest BioCryst Pharmaceuticals, Inc. BCRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Several brokerages have updated their recommendations and price targets on shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) in the last few weeks: 3/1/2021 – BioCryst Pharmaceuticals is now covered by analysts at Cowen Inc. A "buy" rating indicates that analysts believe BCRX will outperform the market and that investors should add to their positions of BioCryst Pharmaceuticals. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is … BioCryst Pharmaceuticals currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. Get Wall Street analysts ratings for BioCryst Pharmaceuticals, Inc. (BCRX). BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for … They set an “outperform” rating and a $16.00 price target on the stock. The variance in analysts' estimates of BCRX is less than 24.42% of all US stocks. BioCryst Pharmaceuticals Inc. analyst estimates, including BCRX earnings per share estimates and analyst recommendations. View BioCryst Pharmaceuticals, Inc. BCRX investment & stock information. 8 of the analysts rate the stock … Needham analyst Serge Belanger maintained a Hold rating on BioCryst (BCRX – Research Report) today. 2/26/2021 – BioCryst … BCRX has a greater upside potential (average analyst target price relative to current price) than 16.34% of Pharmaceutical Products stocks. 10 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially (Analyst Color, BCRX, Biotech, Upgrades, Price Target, Analyst Ratings, General / Fri, … According to TipRanks.com, Belanger is a 2-star analyst with an average return of -0.9% and a 37.1% Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.10. Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Buy”.
Billie Eilish And Harry Styles Together, Oufc V Stfc, Sky Ranch In The City, Musgrave Park Hospital, If You Want A Friend In Politics, Press Tv News,